NYSE:CTLT - Catalent Stock Price, Price Target & More

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 1st. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.06. The firm earned $627.90 million during the quarter, compared to the consensus estimate of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The business's revenue was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.38 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

Catalent updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

14 Wall Street analysts have issued twelve-month target prices for Catalent's shares. Their predictions range from $38.00 to $50.00. On average, they expect Catalent's stock price to reach $45.8182 in the next year. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Ratings for Catalent.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

Media coverage about CTLT stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalent earned a media sentiment score of 0.09 on Accern's scale. They also gave media coverage about the company an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Catalent's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Foundry Partners LLC (0.03%), Municipal Employees Retirement System of Michigan (0.02%), Amalgamated Bank (0.02%), Sit Investment Associates Inc. (0.01%), Bank of Montreal Can (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Foundry Partners LLC, Bank of Montreal Can and Fortaleza Asset Management Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., State of Alaska Department of Revenue, Amalgamated Bank, Hartford Investment Management Co., Oakbrook Investments LLC and Atria Investments LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $43.34.

Catalent has a market capitalization of $5.77 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]